Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

The importance of early antihypertensive efficacy: the role of angiotensin II receptor blocker therapy

Journal of Human Hypertension volume 20, pages 169–175 (2006)Cite this article

Abstract

Desirable features of antihypertensive agents include efficacy, tolerability, prolonged duration of action and rapid achievement of target blood pressure (BP). Recent studies have examined the relationship between the onset of antihypertensive effect and cardiovascular events. Data from the Valsartan Antihypertensive Long-term Use Evaluation (VALUE), the Study on Cognition and Prognosis in the Elderly (SCOPE), and the Systolic Hypertension in Europe (Syst-Eur) trials support the hypothesis that the time it takes to reach target BP influences cardiovascular outcomes. VALUE, which compared BP-lowering and clinical event rates between patients treated with the angiotensin II receptor blocker (ARB) valsartan or the calcium channel blocker (CCB) amlodipine as well as between those who achieved immediate or delayed BP control, provides the strongest evidence of this to date. Additional data from SCOPE and Syst-Eur suggest that delays of 3 months to 2 years in starting antihypertensive therapy can increase the risk of certain cardiovascular end points, especially stroke. These data suggest that it may be beneficial to examine the efficacy of antihypertensive agents, not only long term, but also at earlier times to assess the onset and impact of early antihypertensive effect. The ARB olmesartan medoxomil (olmesartan) and the CCB amlodipine were compared in a randomized, double-blind, placebo-controlled clinical trial, which demonstrated that the onset of antihypertensive effect of olmesartan is comparable with that of amlodipine. Another study demonstrated that more patients treated with olmesartan achieved target BPs within 2 weeks of treatment compared with the ARBs losartan, valsartan and irbesartan.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003; 42: 1206–1252.

    Article  CAS  PubMed  Google Scholar 

  2. European Society of Hypertension–European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension–European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–1053.

  3. Hajjar I, Kotchen TA . Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA 2003; 290: 199–206.

    Article  PubMed  Google Scholar 

  4. World Health Organization. World Health Report 2002: reducing risks promoting healthy life. 2002 cited; Available from: http://www.who.int/whr/2002.

  5. Nesbitt SD, Julius S . Prehypertension: a possible target for antihypertensive medication. Curr Hypertens Rep 2000; 2: 356–361.

    Article  CAS  PubMed  Google Scholar 

  6. Lenfant C, Roccella EJ . A call to action for more aggressive treatment of hypertension. J Hypertens Suppl 1999; 17: S3–S7.

    CAS  PubMed  Google Scholar 

  7. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000; 36: 646–661.

    Article  CAS  PubMed  Google Scholar 

  8. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022–2031.

    Article  CAS  PubMed  Google Scholar 

  9. Benz JR, Black HR, Graff A, Reed A, Fitzsimmons S, Shi Y . Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. J Hum Hypertens 1998; 12: 861–866.

    Article  CAS  PubMed  Google Scholar 

  10. Cappuccio FP, Markandu ND, Singer DR, Buckley MG, Miller MA, Sagnella GA et al. A double-blind crossover study of the effect of concomitant diuretic therapy in hypertensive patients treated with amlodipine. Am J Hypertens 1991; 4: 297–302.

    Article  CAS  PubMed  Google Scholar 

  11. Mann J, Julius S . The valsartan antihypertensive long-term use evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Press 1998; 7: 176–183.

    Article  CAS  PubMed  Google Scholar 

  12. Lindholm LH . Valsartan treatment of hypertension – does VALUE add value? Lancet 2004; 363: 2010–2011.

    Article  PubMed  Google Scholar 

  13. Weber MA, Julius S, Kjeldsen SE, Brunner HR, Ekman S, Hansson L et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004; 363: 2049–2051.

    Article  CAS  PubMed  Google Scholar 

  14. Bloch MJ, Basile J . Analysis of recent papers in hypertension: there is value in early blood pressure reduction. J Clin Hypertens (Greenwich) 2004; 6: 598–600.

    Article  Google Scholar 

  15. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B et al. The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875–886.

    Article  CAS  PubMed  Google Scholar 

  16. Papademetriou V, Farsang C, Elmfeldt D, Hofman A, Lithell H, Olofsson B et al. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol 2004; 44: 1175–1180.

    CAS  PubMed  Google Scholar 

  17. Trenkwalder P, Elmfeldt D, Hofman A, Lithell H, Olofsson B, Papademetriou V et al. The study on cognition and prognosis in the elderly (SCOPE) – major CV events and stroke in subgroups of patients. Blood Press 2005; 14: 31–37.

    Article  PubMed  Google Scholar 

  18. Staessen JA, Thijisq L, Fagard R, Celis H, Birkenhager WH, Bulpitt CJ et al. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J Hypertens 2004; 22: 847–857.

    Article  CAS  PubMed  Google Scholar 

  19. Julius S, Kjeldsen SE, Brunner H, Hansson L, Platt F, Ekman S et al. VALUE trial: long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. Am J Hypertens 2003; 16: 544–548.

    Article  PubMed  Google Scholar 

  20. Bakris GL, Weir MR . Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches. J Clin Hypertens (Greenwich) 2003; 5: 202–209.

    Article  CAS  Google Scholar 

  21. Kassler-Taub K, Littlejohn T, Elliott W, Ruddy T, Adler E . Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan/Losartan study investigators. Am J Hypertens 1998; 11: 445–453.

    Article  CAS  PubMed  Google Scholar 

  22. Hedner T, Oparil S, Rasmussen K, Rapelli A, Gatlin M, Kobi P et al. A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension. Am J Hypertens 1999; 12: 414–417.

    Article  CAS  PubMed  Google Scholar 

  23. Mallion J, Siche J, Lacourciere Y . ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J Hum Hypertens 1999; 13: 657–664.

    Article  CAS  PubMed  Google Scholar 

  24. Chrysant SG, Marbury TC, Robinson TD . Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension. J Hum Hypertens 2003; 17: 425–432.

    Article  CAS  PubMed  Google Scholar 

  25. Chrysant SG, Wang A . Olmesartan medoxomil lowers blood pressure as rapidly as amlodipine besylate in patients with mild to moderate hypertension: results of a randomized, double-blind, placebo-controlled study [abstract]. Am J Hypertens 2004; 17: 102A Abstract P-188.

    Google Scholar 

  26. Data on file. Sankyo Pharma, Inc.: Parsippany, NJ, 2003.

  27. Oparil S, Williams D, Chrysant SG, Marbury TC, Neutel JM . Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens 2001; 3: 283–291, 318.

    Article  CAS  Google Scholar 

  28. The sixth report of the Joint National Committee on prevention, detection, evaluation, treatment of high blood pressure. Arch Intern Med 1997; 157: 2413–2446.

  29. Chrysant SG . Stroke prevention with losartan in the context of other antihypertensive drugs. Drugs Today (Barc) 2004; 40: 791–801.

    Article  CAS  Google Scholar 

  30. Fournier A, Messerli FH, Achard JM, Fernandez L . Cerebroprotection mediated by angiotensin II: a hypothesis supported by recent randomized clinical trials. J Am Coll Cardiol 2004; 43: 1343–1347.

    Article  PubMed  Google Scholar 

  31. Drexler H . Factors involved in the maintenance of endothelial function. Am J Cardiol 1998; 82: 3S–4S.

    Article  CAS  PubMed  Google Scholar 

  32. Unger T . The role of the renin–angiotensin system in the development of cardiovascular disease. Am J Cardiol 2002; 89: 3A–9A; discussion 10A.

    Article  CAS  PubMed  Google Scholar 

  33. Slaninka-Miceska M, Bogdanska J, Korneti P, Kostova E, Jovanoska E, Petrov S . Effect of angiotensin II type 1 (AT1) receptor antagonist on the endothelial dysfunction in spontaneously hypertensive rats in correlation with the nitric oxide system. Bratisl Lek Listy 2003; 104: 342–346.

    CAS  PubMed  Google Scholar 

  34. Bragulat E, Larrousse M, Coca A, de la Sierra A . Effect of long-term irbesartan treatment on endothelium-dependent vasodilation in essential hypertensive patients. Br J Biomed Sci 2003; 60: 191–196.

    Article  CAS  PubMed  Google Scholar 

  35. Mogensen CE . The reno-protective role of AT(1)-receptor blockers. J Hum Hypertens 2002; 16(Suppl 3): S52–S58.

    Article  CAS  PubMed  Google Scholar 

  36. Scheen AJ . Renin–angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta analysis of randomised clinical trials. Diabetes Metab 2004; 30: 487–496.

    Article  CAS  PubMed  Google Scholar 

  37. Jokisalo E, Enlund H, Halonen P, Takala J, Kumpusalo E . Factors related to poor control of blood pressure with antihypertensive drug therapy. Blood Press 2003; 12: 49–55.

    PubMed  Google Scholar 

  38. Berlowitz DR, Ash AS, Hickey EC, Friedman RH, Glickman M, Kader B et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998; 339: 1957–1963.

    Article  CAS  PubMed  Google Scholar 

  39. Oliveria SA, Lapuerta P, McCarthy BD, L'Italien GJ, Berlowitz DR, Asch SM . Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med 2002; 162: 413–420.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by Sankyo Pharma Inc.

Author information

Authors and Affiliations

  1. Ralph H Johnson VA Medical Center, Medical University of South Carolina, Charleston, SC, USA

    J N Basile

  2. Oklahoma Cardiovascular and Hypertension Center and the University of Oklahoma School of Medicine, Oklahoma City, OK, USA

    S Chrysant

Authors
  1. J N Basile
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Chrysant
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J N Basile.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Basile, J., Chrysant, S. The importance of early antihypertensive efficacy: the role of angiotensin II receptor blocker therapy. J Hum Hypertens 20, 169–175 (2006). https://doi.org/10.1038/sj.jhh.1001972

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.jhh.1001972

Keywords

This article is cited by

Search

Advanced search

Quick links